** Shares of medtech firm Senseonics Holdings rise 12.7% to 44 cents
** Co and Ascensia Diabetes Care announce that the U.S. FDA has cleared its continuous glucose monitoring system (CGM) called Eversense 365, that can be worn for one year
** The CGM is for people with Type 1 and Type 2 diabetes aged 18 years and older
** The device has a sensor that can be worn for a year, compared to every 10-14 days with short-term CGM systems, co says
** Expects to initiate the US launch of Eversense 365 US in the fourth quarter of 2024
** Including session moves, stock down 23.9% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.